Home
October 2009 November 2009 December 2009
Su Mo Tu We Th Fr Sa
Week 45 1 2 3 4 5 6 7
Week 46 8 9 10 11 12 13 14
Week 47 15 16 17 18 19 20 21
Week 48 22 23 24 25 26 27 28
Week 49 29 30
Reach urologists

Peyronie's disease: Evolving surgical management and the role of phosphodiesterase 5 inhibitors - Abstract Show Comments PDF Print E-mail
  
Tuesday, 29 September 2009

Division of Urology, Department of Surgery, University of Western Ontario, London, ON

This email address is being protected from spam bots, you need Javascript enabled to view it

Peyronie's disease (PD) is a fibrotic disorder of the tunica albuginea of the penis. It is characterized by different degrees of penile curvature and sexual dysfunction. Several medical treatments have been employed to manage the disorder, with variable success rates. Surgical therapy is reserved for patients with severe penile deformity that fails to improve with medical treatment and impedes coital function. The advantages and disadvantages of various surgical approaches have long been debated. Herein, we describe the evolving surgical techniques for PD using knowledge obtained from the contemporary literature. In addition, we discuss the emerging data regarding the role of phosphodiesterase 5 inhibitors in the management of PD.

Written by:
Al-Shaiji TF, Brock GB   Are you the author?

Reference:
ScientificWorldJournal. 2009 Aug 31;9:822-45
10.1100/tsw.2009.101

PubMed Abstract
PMID: 19734958

UroToday.com Peyronie's Disease Section

Reader Comments

Please log-in or register in order to submit comments.

Powered by AkoComment!

 
User Rating: / 0
PoorBest


 

Bookmark and Share
< Prev   Next >

Member's Section

Login

Sign Up

Quick Search

Featured Conference

Media and Publisher

Advertising Rates
Reprints

Working with Industry

Case Studies
Sponsorship Opportunities